{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:00:02Z","timestamp":1792598402779,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":251,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["26795"],"award-info":[{"award-number":["26795"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG2018\u201321339"],"award-info":[{"award-number":["IG2018\u201321339"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","award":["MFAG2022-27826"],"award-info":[{"award-number":["MFAG2022-27826"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","award":["MFGA2018\u201321505"],"award-info":[{"award-number":["MFGA2018\u201321505"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ctrv.2023.102530","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T20:59:24Z","timestamp":1677531564000},"page":"102530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":201,"special_numbering":"C","title":["Role of FGFR3 in bladder cancer: Treatment landscape and future challenges"],"prefix":"10.1016","volume":"115","author":[{"given":"Claudia Maria","family":"Ascione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Santaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102530_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2023.102530_b0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","article-title":"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas","volume":"23","author":"Cappellen","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2023.102530_b0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/1541-7786.MCR-15-0497","article-title":"Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation","volume":"14","author":"Nelson","year":"2016","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.4297","article-title":"Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours","volume":"232","author":"Parker","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2023.102530_b0030","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0035","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.mayocp.2017.07.010","article-title":"Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer","volume":"92","author":"Giridhar","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ctrv.2023.102530_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2023.102530_b0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and Risk Factors of Urothelial Bladder Cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2023.102530_b0050","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2023.102530_b0055","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00345-018-2544-8","article-title":"Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?","volume":"37","author":"Schardt","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.ctrv.2023.102530_b0060","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of Patients With Metastatic Urothelial Cancer \u201cUnfit\u201d for Cisplatin-Based Chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0065","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102530_b0075","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102530_b0080","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0085","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2023.102530_b0090","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315\u201322. https:\/\/doi.org\/10.1038\/nature12965.","DOI":"10.1038\/nature12965"},{"key":"10.1016\/j.ctrv.2023.102530_b0095","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2023.102530_b0100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2023.102530_b0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2023.102530_b0110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2017.02.018","article-title":"FGFR a promising druggable target in cancer: Molecular biology and new drugs","volume":"113","author":"Porta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2023.102530_b0115","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.yexcr.2007.10.029","article-title":"The cell surface receptor FGFRL1 forms constitutive dimers that promote cell adhesion","volume":"314","author":"Rieckmann","year":"2008","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0120","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00018-010-0576-3","article-title":"Biology of FGFRL1, the fifth fibroblast growth factor receptor","volume":"68","author":"Trueb","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ctrv.2023.102530_b0125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2023.102530_b0130","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1101\/gad.990702","article-title":"FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease","volume":"16","author":"Ornitz","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2023.102530_b0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0092-8674(00)81069-7","article-title":"Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth","volume":"84","author":"Deng","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2023.102530_b0140","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ng0496-390","article-title":"Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3","volume":"12","author":"Colvin","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2023.102530_b0145","doi-asserted-by":"crossref","first-page":"e1003369","DOI":"10.1371\/journal.ppat.1003369","article-title":"Identification of Fibroblast Growth Factor Receptor 3 (FGFR3) as a Protein Receptor for Botulinum Neurotoxin Serotype A (BoNT\/A)","volume":"9","author":"Jacky","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ctrv.2023.102530_b0150","first-page":"4627","article-title":"The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain","volume":"11","author":"Johnson","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2023.102530_b0155","first-page":"82","article-title":"Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities","volume":"12","author":"Werner","year":"1992","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2023.102530_b0160","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.bjc.6601249","article-title":"FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells","volume":"89","author":"Sturla","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0165","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor Specificity of the Fibroblast Growth Factor Family","volume":"281","author":"Zhang","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2023.102530_b0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ctrv.2023.102530_b0175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.yexcr.2004.11.012","article-title":"Cell responses to FGFR3 signalling: growth, differentiation and apoptosis","volume":"304","author":"L\u2019H\u00f4te","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00774-008-0009-7","article-title":"FGFR3-related dwarfism and cell signaling","volume":"27","author":"Harada","year":"2009","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.ctrv.2023.102530_b0185","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/MCB.16.3.977","article-title":"Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction","volume":"16","author":"Mohammadi","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2023.102530_b0190","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1091\/mbc.12.4.931","article-title":"Identification of Tyrosine Residues in Constitutively Activated Fibroblast Growth Factor Receptor 3 Involved in Mitogenesis, Stat Activation, and Phosphatidylinositol 3-Kinase Activation","volume":"12","author":"Hart","year":"2001","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.ctrv.2023.102530_b0195","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0092-8674(00)80252-4","article-title":"A Lipid-Anchored Grb2-Binding Protein That Links FGF-Receptor Activation to the Ras\/MAPK Signaling Pathway","volume":"89","author":"Kouhara","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2023.102530_b0200","doi-asserted-by":"crossref","first-page":"6684","DOI":"10.1073\/pnas.052138899","article-title":"FRS2\u03b1 attenuates FGF receptor signaling by Grb2- mediated recruitment of the ubiquitin ligase Cbl","volume":"99","author":"Wong","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ctrv.2023.102530_b0205","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1097-2765(02)00689-5","article-title":"The Docking Protein FRS2\u03b1 Controls a MAP Kinase-Mediated Negative Feedback Mechanism for Signaling by FGF Receptors","volume":"10","author":"Lax","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2023.102530_b0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cytogfr.2005.01.007","article-title":"Mechanisms underlying differential responses to FGF signaling","volume":"16","author":"Dailey","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ctrv.2023.102530_b0215","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1128\/MCB.24.13.5657-5666.2004","article-title":"The Docking Protein Gab1 Is an Essential Component of an Indirect Mechanism for Fibroblast Growth Factor Stimulation of the Phosphatidylinositol 3-Kinase\/Akt Antiapoptotic Pathway","volume":"24","author":"Lamothe","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2023.102530_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188595","article-title":"FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors","volume":"1876","author":"Servetto","year":"2021","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0225","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2023.102530_b0230","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1158\/1078-0432.CCR-20-3905","article-title":"Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer","volume":"27","author":"Servetto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0235","doi-asserted-by":"crossref","first-page":"A321","DOI":"10.2741\/A321","article-title":"FGF signaling in skeletal development","volume":"3","author":"Ornitz","year":"1998","journal-title":"Front Biosci"},{"key":"10.1016\/j.ctrv.2023.102530_b0240","first-page":"5068","article-title":"A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1","volume":"11","author":"Mohammadi","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2023.102530_b0245","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/218142","article-title":"Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration","volume":"1","author":"Yun","year":"2010","journal-title":"J Tissue Eng"},{"key":"10.1016\/j.ctrv.2023.102530_b0250","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1074\/jbc.M308743200","article-title":"Critical Role of STAT5 Activation in Transformation Mediated by ZNF198-FGFR1","volume":"279","author":"Heath","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2023.102530_b0255","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1038\/sj.onc.1203650","article-title":"Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4","volume":"19","author":"Hart","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2023.102530_b0260","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ydbio.2005.09.011","article-title":"Functions and regulations of fibroblast growth factor signaling during embryonic development","volume":"287","author":"Thisse","year":"2005","journal-title":"Dev Biol"},{"key":"10.1016\/j.ctrv.2023.102530_b0265","doi-asserted-by":"crossref","DOI":"10.1126\/stke.2282004pe17","article-title":"Promotion and Attenuation of FGF Signaling Through the Ras-MAPK Pathway","volume":"2004","author":"Tsang","year":"2004","journal-title":"Sci STKE"},{"key":"10.1016\/j.ctrv.2023.102530_b0270","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1242\/dev.02701","article-title":"Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development","volume":"134","author":"Li","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.ctrv.2023.102530_b0275","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1128\/MCB.18.7.3966","article-title":"Binding of Shp2 Tyrosine Phosphatase to FRS2 Is Essential for Fibroblast Growth Factor-Induced PC12 Cell Differentiation","volume":"18","author":"Hadari","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2023.102530_b0285","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine through an International Consortium","volume":"7","author":"Andr\u00e9","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2023.102530_b0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ctrv.2023.102530_b0295","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of Targetable FGFR Gene Fusions in Diverse Cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2023.102530_b0300","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","article-title":"Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations","volume":"26","author":"Gallo","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ctrv.2023.102530_b0305","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science (80-)"},{"key":"10.1016\/j.ctrv.2023.102530_b0310","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ng.2798","article-title":"Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation","volume":"45","author":"Guo","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2023.102530_b0315","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","article-title":"Detection, Characterization, and Inhibition of FGFR\u2013TACC Fusions in IDH Wild-type Glioma","volume":"21","author":"Di Stefano","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0320","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0325","doi-asserted-by":"crossref","DOI":"10.1172\/JCI67144","article-title":"The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma","author":"Parker","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2023.102530_b0330","first-page":"23","article-title":"The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans*","volume":"21","author":"Vajo","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2023.102530_b0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ng0696-233","article-title":"Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia","volume":"13","author":"Naski","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2023.102530_b0340","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/sj.onc.1210399","article-title":"Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer","volume":"26","author":"Tomlinson","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2023.102530_b0345","doi-asserted-by":"crossref","first-page":"28","DOI":"10.18063\/cp.v3i1.302","article-title":"The Role of FGFR3 in the Diagnosis and Treatment of Bladder Cancer: A Review","volume":"3","author":"Wei","year":"2021","journal-title":"Cancer Plus"},{"key":"10.1016\/j.ctrv.2023.102530_b0350","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bpj.2014.11.3460","article-title":"Effect of Thanatophoric Dysplasia Type I Mutations on FGFR3 Dimerization","volume":"108","author":"Del Piccolo","year":"2015","journal-title":"Biophys J"},{"key":"10.1016\/j.ctrv.2023.102530_b0355","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.2002.17.5.860","article-title":"Differential Activation of Cysteine-Substitution Mutants of Fibroblast Growth Factor Receptor 3 Is Determined by Cysteine Localization","volume":"17","author":"Adar","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0360","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/j.1460-2075.1996.tb00384.x","article-title":"Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia","volume":"15","author":"Webster","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.ctrv.2023.102530_b0365","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa)","volume":"158","author":"Billerey","year":"2001","journal-title":"Tumors Am J Pathol"},{"key":"10.1016\/j.ctrv.2023.102530_b0370","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","article-title":"Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia","volume":"78","author":"Shiang","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2023.102530_b0375","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2023.102530_b0380","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer","volume":"19","author":"Andr\u00e9","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0385","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","article-title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo","volume":"104","author":"Lamont","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0395","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2023.102530_b0400","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-16-2267","article-title":"A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12\u2013157","volume":"23","author":"Hahn","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0405","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.ejca.2014.10.013","article-title":"Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma","volume":"50","author":"Milowsky","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0410","doi-asserted-by":"crossref","unstructured":"Javle MM, Abou-Alfa GK, Macarulla T, Personeni N, Adeva J, Bergamo F, et al. Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01. J Clin Oncol 2022;40:427\u2013427. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.427.","DOI":"10.1200\/JCO.2022.40.4_suppl.427"},{"key":"10.1016\/j.ctrv.2023.102530_b0415","doi-asserted-by":"crossref","unstructured":"Mazzaferro V, El-Rayes BF, Droz dit Busset M, Cotsoglou C, Harris WP, Damjanov N, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 2019;120:165\u201371. https:\/\/doi.org\/10.1038\/s41416-018-0334-0.","DOI":"10.1038\/s41416-018-0334-0"},{"key":"10.1016\/j.ctrv.2023.102530_b0420","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0425","doi-asserted-by":"crossref","first-page":"e1711","DOI":"10.1634\/theoncologist.2020-0334","article-title":"Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer","volume":"25","author":"Garje","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2023.102530_b0430","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS590","article-title":"FIDES-02, a phase Ib\/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations","volume":"38","author":"Chaudhry","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0435","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk\/Benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.ctrv.2023.102530_b0440","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0445","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102530_b0450","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2019.1671190","article-title":"Erdafitinib for the treatment of urothelial cancer","volume":"19","author":"Marandino","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2023.102530_b0455","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0460","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy283.129","article-title":"Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M\/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study","volume":"29","author":"Loriot","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0465","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.32224","article-title":"Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models","volume":"145","author":"Gr\u00fcnewald","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0470","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0475","article-title":"FORT-1: Phase II\/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 \/ 3 mRNA Expression","author":"Sternberg","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0480","doi-asserted-by":"crossref","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2023.102530_b0485","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1\u20133 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0490","doi-asserted-by":"crossref","unstructured":"Necchi A, Pouessel D, Leibowitz-Amit R, Flechon A, Gupta S, Barthelemy P, et al. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)\/FGF receptor (FGFR) genetic alterations (. Ann Oncol 2018;29:viii319\u201320. https:\/\/doi.org\/10.1093\/annonc\/mdy283.109.","DOI":"10.1093\/annonc\/mdy283.109"},{"key":"10.1016\/j.ctrv.2023.102530_b0495","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2023.102530_b0500","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1\u20133 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Stu","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0505","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1\u20133 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2023.102530_b0510","doi-asserted-by":"crossref","unstructured":"Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits JH, Quinn DI, Petrylak DP, et al. Infigratinib and treatment response in advanced\/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings. J Clin Oncol 2020;38:5038\u20135038. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5038.","DOI":"10.1200\/JCO.2020.38.15_suppl.5038"},{"key":"10.1016\/j.ctrv.2023.102530_b0515","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib Is a Novel Irreversible FGFR 1\u20134 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0520","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an Irreversible FGFR1\u20134 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF \/ FGFR Aberrations: A Phase I Dose-Expansion Study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2023.102530_b0525","doi-asserted-by":"crossref","unstructured":"Koshkin VS, Sonpavde GP, Hwang C, Mellado B, Tomlinson G, Shimura M, et al. Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study. J Clin Oncol 2022;40:501\u2013501. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.501.","DOI":"10.1200\/JCO.2022.40.6_suppl.501"},{"key":"10.1016\/j.ctrv.2023.102530_b0530","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284\/Debio 1347, a Novel Selective FGFR Inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2023.102530_b0535","doi-asserted-by":"crossref","unstructured":"Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, et al. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clin Cancer Res 2019;25:2699\u2013707. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1959.","DOI":"10.1158\/1078-0432.CCR-18-1959"},{"key":"10.1016\/j.ctrv.2023.102530_b0540","doi-asserted-by":"crossref","unstructured":"Cleary JM, Iyer G, Oh D-Y, Mellinghoff IK, Goyal L, Ng MCH, et al. Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. J Clin Oncol 2020;38:3603\u20133603. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.3603.","DOI":"10.1200\/JCO.2020.38.15_suppl.3603"},{"key":"10.1016\/j.ctrv.2023.102530_b0545","doi-asserted-by":"crossref","unstructured":"Hyman DM, Goyal L, Grivas P, Meric-Bernstam F, Tabernero J, Hu Y, et al. FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. J Clin Oncol 2019;37:TPS3157\u2013TPS3157. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS3157.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3157"},{"key":"10.1016\/j.ctrv.2023.102530_b0550","doi-asserted-by":"crossref","first-page":"F1577","DOI":"10.1152\/ajprenal.00463.2006","article-title":"Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1\u03b1-hydroxylase expression in vitro","volume":"293","author":"Perwad","year":"2007","journal-title":"Am J Physiol Physiol"},{"key":"10.1016\/j.ctrv.2023.102530_b0555","doi-asserted-by":"crossref","unstructured":"Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P. Petrylak D, et al. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1\u20133 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3\u2013altered Advanced\/Metastatic Urothelial Carcinoma. Eur Urol 2020;78:916\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.002.","DOI":"10.1016\/j.eururo.2020.08.002"},{"key":"10.1016\/j.ctrv.2023.102530_b0560","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1158\/1078-0432.CCR-05-0282","article-title":"Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation","volume":"11","author":"Mart\u00ednez-Torrecuadrada","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0565","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz249.016","article-title":"Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22","volume":"30","author":"Siefker-Radtke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0570","doi-asserted-by":"crossref","unstructured":"Mellado B, Castellano DE, Pang S, Urun Y, Park SH, Vaishampayan UN, et al. Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). J Clin Oncol 2019;37:4547\u20134547. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.4547.","DOI":"10.1200\/JCO.2019.37.15_suppl.4547"},{"key":"10.1016\/j.ctrv.2023.102530_b0575","doi-asserted-by":"crossref","unstructured":"Bellmunt J, Picus J, Kohli M, Arriaga YE, Milowsky MI, Currie G, et al. FIERCE-21: Phase 1b\/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R\/R) metastatic urothelial carcinoma (mUCC). J Clin Oncol 2018;36:4534\u20134534. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.4534.","DOI":"10.1200\/JCO.2018.36.15_suppl.4534"},{"key":"10.1016\/j.ctrv.2023.102530_b0580","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","article-title":"Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice","volume":"119","author":"Qing","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2023.102530_b0585","doi-asserted-by":"crossref","unstructured":"Surguladze D, Pennello A, Ren X, Mack T, Rigby A, Balderes P, et al. Abstract 4835: LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions. Cancer Res 2019;79:4835\u20134835. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-4835.","DOI":"10.1158\/1538-7445.AM2019-4835"},{"key":"10.1016\/j.ctrv.2023.102530_b0590","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s10637-021-01146-x","article-title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody\u2013drug conjugate, in patients with advanced or metastatic cancer","volume":"39","author":"Kollmannsberger","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2023.102530_b0595","doi-asserted-by":"crossref","first-page":"S1303","DOI":"10.1016\/j.annonc.2021.08.2103","article-title":"LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study","volume":"32","author":"Powles","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctrv.2023.102530_b0600","doi-asserted-by":"crossref","unstructured":"Rosenberg JE, Gajate P, Morales-Barrera R, Lee J-L, Necchi A, Penel N, et al. Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib\/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexp. J Clin Oncol 2020;38:5014\u20135014. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5014.","DOI":"10.1200\/JCO.2020.38.15_suppl.5014"},{"key":"10.1016\/j.ctrv.2023.102530_b0605","doi-asserted-by":"crossref","unstructured":"Koshkin VS, Sonpavde GP, Hwang C, Mellado B, Tomlinson G, Shimura M, et al. Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study. Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 501-501. DOI: 10.1200\/JCO.2022.40.6_suppl.501.","DOI":"10.1200\/JCO.2022.40.6_suppl.501"},{"key":"10.1016\/j.ctrv.2023.102530_b0610","doi-asserted-by":"crossref","unstructured":"Pal SK, Daneshmand S, Matin SF, Loriot Y, Sridhar SS, Grivas P, et al. PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations. J Clin Oncol 2020;38:TPS600\u2013TPS600. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.TPS600.","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS600"},{"key":"10.1016\/j.ctrv.2023.102530_b0615","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0620","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0625","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2023.102530_b0630","doi-asserted-by":"crossref","unstructured":"Guercio BJ, Sarfaty M, Teo MY, Funt SA, Lee C-H, Aggen DH, et al. Abstract 3410: Identifying potential mechanisms of resistance to erdafitinib (erda) via longitudinal analysis of circulating tumor (ct)-DNA of patients (pts) with advanced\/metastatic urothelial cancer (mUC). Cancer Res 2022;82:3410\u20133410. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-3410.","DOI":"10.1158\/1538-7445.AM2022-3410"},{"key":"10.1016\/j.ctrv.2023.102530_b0635","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ebiom.2015.02.009","article-title":"The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study","volume":"2","author":"Bunney","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2023.102530_b0640","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-12-0569","article-title":"Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3 -Mutant Cancer","volume":"3","author":"Herrera-Abreu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2023.102530_b0645","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1535-7163.MCT-15-1010","article-title":"Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398","volume":"16","author":"Datta","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2023.102530_b0650","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.eururo.2017.01.021","article-title":"A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma","volume":"71","author":"Wang","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2023.102530_b0655","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.3390\/cancers13194891","article-title":"Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling","volume":"13","author":"Xiao","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102530_b0660","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12885-022-09478-4","article-title":"Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer","volume":"22","author":"Weickhardt","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0665","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-17-0478","article-title":"Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung Cancer","volume":"23","author":"Malchers","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0670","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jmoldx.2021.12.012","article-title":"Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling","volume":"24","author":"Silverman","year":"2022","journal-title":"J Mol Diagnostics"},{"key":"10.1016\/j.ctrv.2023.102530_b0675","doi-asserted-by":"crossref","unstructured":"Moss TJ, Rodon Ahnert J, Oakley HD, Kahle M, Karp DD, Pant S, et al. Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. J Clin Oncol 2019;37:3056\u20133056. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.3056.","DOI":"10.1200\/JCO.2019.37.15_suppl.3056"},{"key":"10.1016\/j.ctrv.2023.102530_b0680","doi-asserted-by":"crossref","first-page":"e16061","DOI":"10.1200\/JCO.2020.38.15_suppl.e16061","article-title":"FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA","volume":"38","author":"De Dios","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0685","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2023.102530_b0690","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102530_b0695","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2023.102530_b0700","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.459.11.2","article-title":"Fibroblast Growth Factor Receptor 3 Is Overexpressed in Urinary Tract Carcinomas and Modulates the Neoplastic Cell Growth","volume":"11","author":"G\u00f3mez-Rom\u00e1n","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102530_b0705","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ebiom.2018.06.011","article-title":"Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy","volume":"35","author":"Yang","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2023.102530_b0710","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","article-title":"Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1\/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer","volume":"76","author":"Wang","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2023.102530_b0715","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102530_b0720","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722300021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722300021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:29:05Z","timestamp":1759656545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722300021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":143,"alternative-id":["S030573722300021X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102530","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102530"}}